top of page


  • Rimonabant and Parkinson's disease: effects on motor symptom. IP: AO.  Junta de Comunidades de Castilla La Mancha  (SBPLY721/180501/000141).

  • Post-COVID-19 fatigue syndrome: alterations in the excitability of the motor system and the use of Rimonabant as a treatment (RIMOCOVID). IP: AO. Plan Nacional_Ministerio de Ciencia e Innovación (PID2020-117617-RB).

  • Rimonabant for improving walking abilities in spinal cord injury. IP: AO. Instituto de Salud Carlos III (ICI20/00075).

  • Effects of static magnetic fields on the brain: study of the mechanisms. IP: VSL. Fundación Ramón Areces (CIVP20A6617).​

  • European Training on innovative Restorative Protocols for clinical and technological changeable. IP: AO. Comisión Europea (KA202-D7D43DC7).

  • Home detection of pneumonia associated with COVID-19 using an APP and an artificial intelligence algorithm. IP: AO.

  • Effects of CB1 antagonist/inverse agonist (Rimonabant) on walking abilities and endurance in incomplete traumatic SCI: a proof of principle study. IP: AO. International Foundation for Research in Paraplegia (181).

  • Project. IP: AO. Spanish Network of Brain Stimulation.

  • Noninvasive brain stimulation with static magnetic fields: transferring transcranial stimulation from the laboratory to the patient. IP: AO. Ministerio De Economía Y Competitividad (SAF2016-80647-R). 

  • Mental privacy, neurotechnology and disability: ethical, legal and social aspects. IP: AO. ERA-NET NEURON-ISCIII (AC23_2/00006).

bottom of page